Literature DB >> 16973609

The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis.

Charlotta Lindvall1, Nicole C Evans, Cassandra R Zylstra, Yi Li, Caroline M Alexander, Bart O Williams.   

Abstract

Canonical Wnt signaling has emerged as a critical regulatory pathway for stem cells. The association between ectopic activation of Wnt signaling and many different types of human cancer suggests that Wnt ligands can initiate tumor formation through altered regulation of stem cell populations. Here we have shown that mice deficient for the Wnt co-receptor Lrp5 are resistant to Wnt1-induced mammary tumors, which have been shown to be derived from the mammary stem/progenitor cell population. These mice exhibit a profound delay in tumorigenesis that is associated with reduced Wnt1-induced accumulation of mammary progenitor cells. In addition to the tumor resistance phenotype, loss of Lrp5 delays normal mammary development. The ductal trees of 5-week-old Lrp5-/- females have fewer terminal end buds, which are structures critical for juvenile ductal extension presumed to be rich in stem/progenitor cells. Consequently, the mature ductal tree is hypomorphic and does not completely fill the fat pad. Furthermore, Lrp5-/- ductal cells from mature females exhibit little to no stem cell activity in limiting dilution transplants. Finally, we have shown that Lrp5-/- embryos exhibit substantially impaired canonical Wnt signaling in the primitive stem cell compartment of the mammary placodes. These findings suggest that Lrp5-mediated canonical signaling is required for mammary ductal stem cell activity and for tumor development in response to oncogenic Wnt effectors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973609     DOI: 10.1074/jbc.M607571200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.

Authors:  Shruti Goel; Emily N Chin; Saja A Fakhraldeen; Scott M Berry; David J Beebe; Caroline M Alexander
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

Review 2.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

Review 3.  Molecular mechanisms guiding embryonic mammary gland development.

Authors:  Pamela Cowin; John Wysolmerski
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-19       Impact factor: 10.005

4.  Loss of Limb-Bud-and-Heart (LBH) attenuates mammary hyperplasia and tumor development in MMTV-Wnt1 transgenic mice.

Authors:  Kilan Ashad-Bishop; Koteswararao Garikapati; Linsey E Lindley; Merce Jorda; Karoline J Briegel
Journal:  Biochem Biophys Res Commun       Date:  2018-12-01       Impact factor: 3.575

5.  Simulating mouse mammary gland development: cell ageing and its relation to stem and progenitor activity.

Authors:  A Paguirigan; D J Beebe; C M Alexander
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

Review 6.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

7.  Parathyroid hormone-related protein activates Wnt signaling to specify the embryonic mammary mesenchyme.

Authors:  Minoti Hiremath; Pamela Dann; Jennifer Fischer; Daniela Butterworth; Kata Boras-Granic; Julie Hens; Joshua Van Houten; Wei Shi; John Wysolmerski
Journal:  Development       Date:  2012-10-03       Impact factor: 6.868

8.  Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector.

Authors:  Young Chul Kim; Rod J Clark; Erik A Ranheim; Caroline M Alexander
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model.

Authors:  Yi Guo; Elyssa M Rubin; Jun Xie; Xiaolin Zi; Bang H Hoang
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

Review 10.  LRP5 and LRP6 in development and disease.

Authors:  Danese M Joiner; Jiyuan Ke; Zhendong Zhong; H Eric Xu; Bart O Williams
Journal:  Trends Endocrinol Metab       Date:  2013-01       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.